Literature DB >> 32965009

Imbalance between procoagulant factors and natural coagulation inhibitors contributes to hypercoagulability in the critically ill COVID-19 patient: clinical implications.

S Voicu1, M Delrue, B G Chousterman, A Stépanian, P Bonnin, I Malissin, N Deye, M Neuwirth, C Ketfi, A Mebazaa, V Siguret, B Mégarbane.   

Abstract

OBJECTIVE: Coronavirus Disease-2019 (COVID-19) predisposes patients to thrombosis which underlying mechanisms are still incompletely understood. We sought to investigate the balance between procoagulant factors and natural coagulation inhibitors in the critically ill COVID-19 patient and to evaluate the usefulness of hemostasis parameters to identify patients at risk of venous thromboembolic event (VTE). PATIENTS AND METHODS: We conducted an observational study recording VTEs defined as deep vein thrombosis or pulmonary embolism using lower limb ultrasound (92% of the patients), computed tomography pulmonary angiography (6%) and both tests (2%). We developed a comprehensive analysis of hemostasis.
RESULTS: Ninety-two consecutive mechanically ventilated COVID-19 patients (age, 62 years [53-69] (median [25th-75th percentiles]); M/F sex ratio, 2.5; body-mass index, 28 kg/m2 [25-32]; past hypertension (52%) and diabetes mellitus (30%)) admitted to the Intensive Care Unit (ICU) from 03/11/2020 to 5/05/2020, were included. When tested, patients were receiving prophylactic (74%) or therapeutic (26%) anticoagulation. Forty patients (43%) were diagnosed with VTE. Patients displayed inflammatory and prothrombotic profile including markedly elevated plasma fibrinogen (7.7 g/L [6.1-8.6]), D-dimer (3,360 ng/mL [1668-7575]), factor V (166 IU/dL [136-195]) and factor VIII activities (294 IU/dL [223-362]). We evidenced significant discrepant protein C anticoagulant and chromogenic activities, combined with slightly decreased protein S activity. Plasma D-dimer >3,300 ng/mL predicted VTE presence with 78% (95%-confidence interval (95% CI), 62-89) sensitivity, 69% (95% CI, 55-81) specificity, 66% (95% CI, 51-79) positive predictive value and 80% (95% CI, 65-90) negative predictive value [area under the ROC curve, 0.779 (95%CI, 0.681-0.859), p=0.0001].
CONCLUSIONS: Mechanically ventilated COVID-19 patients present with an imbalance between markedly increased factor V/VIII activity and overwhelmed protein C/S pathway. Plasma D-dimer may be a useful biomarker at the bedside for suspicion of VTE.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32965009     DOI: 10.26355/eurrev_202009_22866

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  6 in total

Review 1.  Diagnostic Accuracy of Liquid Biomarkers in Airway Diseases: Toward Point-of-Care Applications.

Authors:  Vivianne Landry; Patrick Coburn; Karen Kost; Xinyu Liu; Nicole Y K Li-Jessen
Journal:  Front Med (Lausanne)       Date:  2022-06-06

2.  Increased anticoagulation reduces proximal deep vein thrombosis in mechanically ventilated COVID-19 patients: Venous thrombosis prevention & COVID-19.

Authors:  Sebastian Voicu; Benjamin G Chousterman; Philippe Bonnin; Nicolas Deye; Isabelle Malissin; Arthur Le Gall; Romain Barthélémy; Laetitia Sutterlin; Giulia Naim; Aymen Mrad; Adrien Pepin-Lehalleur; Matthieu Le Dorze; Charles de Roquetaillade; Jean-Michel Ekhérian; Etienne Gayat; Georgios Sidéris; Alexandre Mebazaa; Bruno Mégarbane
Journal:  J Infect       Date:  2020-11-20       Impact factor: 6.072

Review 3.  Pathophysiological Processes Underlying the High Prevalence of Deep Vein Thrombosis in Critically Ill COVID-19 Patients.

Authors:  Sebastian Voicu; Chahinez Ketfi; Alain Stépanian; Benjamin G Chousterman; Nassim Mohamedi; Virginie Siguret; Alexandre Mebazaa; Bruno Mégarbane; Philippe Bonnin
Journal:  Front Physiol       Date:  2021-01-08       Impact factor: 4.566

4.  A systematic review of biomarkers among hospitalized patients with COVID-19 predictive of venous thromboembolism: A communication from the Predictive and Diagnostic Variables Scientific and Standardization Committee of the ISTH.

Authors:  Scott C Woller; Kerstin de Wit; Helia Robert-Ebadi; Camila Masias; Frederikus A Klok; Paul L den Exter; Pierre-Emmanuel Morange; David Castelli; John-Bjarne Hansen
Journal:  Res Pract Thromb Haemost       Date:  2022-08-26

5.  Comorbidities, sequelae, blood biomarkers and their associated clinical outcomes in the Mount Sinai Health System COVID-19 patients.

Authors:  Agnieszka Brojakowska; Abrisham Eskandari; Malik Bisserier; Jeffrey Bander; Venkata Naga Srikanth Garikipati; Lahouaria Hadri; David A Goukassian; Kenneth M Fish
Journal:  PLoS One       Date:  2021-07-06       Impact factor: 3.752

6.  Blood coagulation parameter abnormalities in hospitalized patients with confirmed COVID-19 in Ethiopia.

Authors:  Shambel Araya; Mintesnot Aragaw Mamo; Yakob Gebregziabher Tsegay; Asegdew Atlaw; Aschalew Aytenew; Abebe Hordofa; Abebe Edao Negeso; Moges Wordofa; Tirhas Niguse; Mahlet Cheru; Zemenu Tamir
Journal:  PLoS One       Date:  2021-06-21       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.